Extracellular vesicle therapy for acute pancreatitis: experimental validation of mesenchymal stem cell-derived nanovesicles
The gut microbiome-immune axis is the primary factor contributing to the aggravation of AP caused by opioids. BMSC-sEVs can be positioned as a novel drug for the treatment of AP, as it effectively regulates gut microbiome-immune crosstalk to coordinate analgesia and inflammation.
Authors
- Qingping Wen (ORCID: https://orcid.org/0000-0003-3999-4770)
- Zhiling Liu
- Yan Liu (ORCID: https://orcid.org/0000-0003-2918-5398)
- Yue Wu (ORCID: https://orcid.org/0000-0002-1396-2407)
- Yiping Liu (ORCID: https://orcid.org/0000-0002-2554-3269)
- Jiaqi Yao (ORCID: https://orcid.org/0000-0002-7822-910X)
Institutions
- Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1186/s40360-025-00975-3
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00